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Abstract
The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as
first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate
Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0
months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval,
0.42-1.08).
Purpose: The present study compared the efficacy of sunitinib and sorafenib as first-line treatment of metastatic clear
cell renal cell carcinoma (mCC-RCC) with favorable or intermediate Memorial Sloan Kettering Cancer Center (MSKCC)
risk. Patients and Methods: Treatment-naive patients with mCC-RCC were randomized to receive open-label
sunitinib followed by sorafenib (SU/SO) or sorafenib followed by sunitinib (SO/SU). The primary endpoint was first-
line progression-free survival (PFS). The secondary endpoints were total PFS and overall survival (OS). Results: Of
the 124 patients enrolled at 39 institutions from February 2010 to July 2012, 120 were evaluated. The median
first-line PFS duration was 8.7 and 7.0 months in the SU/SO and SO/SU groups, respectively (hazard ratio [HR],
0.67; 95% confidence interval [CI], 0.42-1.08). The total PFS and OS were not significantly different between the
SU/SO and SO/SU groups (27.8 and 22.6 months; HR, 0.73; 95% CI, 0.428-1.246; and 38.4 and 30.9 months;
HR, 0.934; 95% CI, 0.588-1.485, respectively). The subgroup analysis revealed that the total PFS with SU/SO was
superior to the total PFS with SO/SU in the patients with favorable MSKCC risk and those with < 5 metastatic
sites). SO/SU was superior to SU/SO for patients without previous nephrectomy. Conclusions: No statistically1Department of Urology, Niigata University Graduate School of Medical and Dental
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Sunitinib Versus Sorafenib for mCC-RCCsignificant differences were found in first-line PFS, total PFS, or OS between the 2 treatment arms (ClinicalTrials.
gov identifier, NCT01481870).
Clinical Genitourinary Cancer, Vol. -, No. -, --- ª 2020 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Renal cell carcinoma (RCC) with clear cell (CC) histologic fea-
tures has been demonstrated to exhibit increased angiogenesis in
concordance with the upregulation of vascular endothelial growth
factor (VEGF), owing to the underlying genetic alteration of von
Hippel Lindau1 or another functionally associated gene.2 Of the
currently approved drugs that target VEGF or its receptors
(VEGFRs), sorafenib was the first to be used for metastatic RCC
(mRCC) in a second-line setting, followed by interferon (IFN)-a.3
The median progression-free survival (mPFS) with sorafenib was 5.5
months compared with 2.8 months with placebo, corresponding to
a hazard ratio (HR) of 0.44 (95% confidence interval [CI],
0.35-0.55; P < .001). In treatment-naive patients with mRCC,
sunitinib was associated with longer survival compared with IFN-a
(mPFS, 11 months with sunitinib vs. 5 months with IFN-a; HR,
0.42; 95% CI, 0.32-0.54; P < .001).4 The efficacy of pazopanib
was also demonstrated to be similar to that of sunitinib in a first-line
setting5 (mPFS, 8.4 months with pazopanib vs. 9.5 months with
sunitinib; 95% CI, 8.3-10.9 and 95% CI, 8.3-11.1, respectively).
Most of the patients in these trials had had disease categorized as
favorable or intermediate risk using the Memorial Sloan Kettering
Cancer Center (MSKCC) criteria. In MSKCC poor-risk patients,
temsirolimus was shown to achieve longer overall survival (OS) than
IFN-a alone.6 In clinical practice, sunitinib and sorafenib can be
chosen as a first-line therapeutic option because of patient status
and/or comorbidities that might be unfavorable for treatment with
sunitinib, pazopanib, or temsirolimus or because of the healthcare
system of the specific country.
The SWITCH study, a prospective, randomized sequential trial
to evaluate 2 sequential therapy protocols (sunitinib followed by
sorafenib [SU/SO] vs. sorafenib followed by sunitinib [SO/SU]),
revealed no differences in first-line PFS (first-PFS), total PFS
(T-PFS), or OS.7 Of the trial subjects, 13% had had a diagnosis of
non-CC RCC.7 However, no direct comparisons were performed
between first-line sunitinib and first-line sorafenib for patients with
metastatic CC-RCC (mCC-RCC) that had been predefined as
favorable or intermediate MSKCC risk groups. Recently, the
combination of nivolumab and ipilimumab was associated with a
significantly longer median OS than that with sunitinib for patients
in the intermediate- and poor-risk groups according to the inter-
national mRCC database consortium (IMDC) criteria,8 which was
not observed in the favorable-risk group. The identification of pa-
tients who can be expected to benefit more from sunitinib as first-
line treatment is warranted.
In the present phase III randomized, open-label trial
(ClinicalTrial.gov identifier, NCT01481870; and University Hos-
pital Medical Information Network [Tokyo, Japan] identifier,nical Genitourinary Cancer Month 2020UMIN00003040), we directly compared the efficacy of sunitinib
and sorafenib in treatment-naive patients with a diagnosis of the




The eligibility criteria included the following: age  18 but  80
years; histologically confirmed RCC; metastatic disease; favorable-
or intermediate-MSKCC risk group; Eastern Cooperative Oncology
Group performance status 0 to 2; and adequate pulmonary, cardiac,
renal, hepatic, and hematologic function. Patients who had received
previous systemic treatment were excluded; however, those who had
received cytokine therapy in a postoperative adjuvant setting and
whose disease had not progressed to metastases during cytokine
therapy were accepted. Additional criteria included measurable
disease according to the Response Evaluation Criteria in Solid
Tumors (RECIST), version 1.1.9
Patients with a diagnosis of cardiovascular disease within 12
months before screening and those with a history of any other
malignant tumor were excluded. The presence of brain metas-
tases (BMs) was an exclusion criterion; however, patients with
stable BMs for 2 months before screening were enrolled in the
present trial.
Study Design
The present study was a phase III randomized, open-label trial of
sunitinib (Sutent; Pfizer) followed by sorafenib (Nexavar; Bayer)
and vice versa. Treatment-naive patients with mRCC were
randomly assigned at a 1:1 ratio to either SU/SO or SO/SU treat-
ment. Randomization was performed according to the presence of
previous nephrectomy (yes vs. no), MSKCC risk group (favorable
vs. intermediate risk), and institution.
Sunitinib was orally administered for a 6-week cycle at a once-
daily dose of 50 mg for 4 weeks, followed by 2 weeks without
treatment. Sorafenib was orally administered at a dosage of 400 mg
twice daily without a break. Patients continued to receive the study
drug until disease progression, unacceptable toxicity, death, or
another reason for discontinuation of the study drug. A dose
reduction of sunitinib (from 50 mg to first, 37.5 mg and then, 25
mg) and sorafenib (from 400 mg twice daily to first, 400 mg once
daily and then, 400 mg every other day) was determined according
to the severity of the adverse events (AEs).
The institutional review board or ethics committee at each
institution approved the present study, which was conducted in
accordance with the Declaration of Helsinki. All patients provided
written informed consent.
Table 1 Baseline Demographics and Clinical Characteristics
Characteristica All Patients
Arm A (Sunitinib to
Sorafenib)
Arm B (Sorafenib to
Sunitinib) P Valueb
Patients 120 57 63
Sex .622
Male 99 46 53
Female 21 11 10
Age, y .510
Median 67 67 66
Range 41-79 41-79 44-79
MSKCC risk group .877
Favorable 26 12 14
Intermediate 94 45 49
Histologic grade .236
1 15 8 7
2 57 22 35
3 38 21 17
cT at initial visit .639
1a 13 4 9
1b 21 12 9
2 24 12 12
3a 26 14 12
3b 20 8 12
3c 0 0 0
4 7 3 4
cN at initial visit .822
0 108 50 58
1 10 5 5
M at initial visit
0 56 25 31
1 64 32 32
Metastatic sites, n .210
1 9 7 2
2 16 9 7
3 24 8 16
4 14 6 8
>4 57 27 30
Lung metastasis .588
Yes 87 40 47
No 33 17 16
Lymph node metastasis .248
Yes 34 19 15
No 86 38 48
Bone metastasis .201
Yes 34 13 21
No 86 44 42
Brain metastasis .071
Yes 6 5 1
No 114 63 62
Liver metastasis .620
Yes 10 4 6
No 110 53 57
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Table 1 Continued
Characteristica All Patients
Arm A (Sunitinib to
Sorafenib)
Arm B (Sorafenib to
Sunitinib) P Valueb
Local and/or renal recurrence
(or metastasis)
.220
Yes 20 12 8
No 100 45 55
Metastases at other sites .894
Yes 33 16 17
No 87 41 46
Surgery for primary lesion .842
Yes 106 50 56
No 14 7 7
Metastasectomy .228
Yes 22 13 9
No 98 44 54
Adjuvant interferon-a treatment .620
Yes 10 4 6
No 110 53 57
Irradiation for brain metastases .137
Yes 5 4 1




Yes 6 3 3
No 114 54 60
Abbreviation: MSKCC ¼ Memorial Sloan Kettering Cancer Center.
aCharacteristics were measured at baseline, except for cT, cN, and M; TNM stage was estimated at the first renal cell carcinoma diagnosis using the 2009 Union Internationale Contre le Cancer/
American Joint Cancer Committee TNM classification; histologic grade was determined using the General Rules of Clinical and Pathological Studies on Renal Cell Carcinoma in Japan (histologic grade
classified as grade 1-3).
bCalculated using the c2 test, except for age, which was calculated using the Welch t test.
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The primary endpoint was first-PFS, which was defined as the
interval from the date of randomization to the date of disease
progression or death from any cause. The secondary endpoints
included the objective response rate (ORR), safety, OS, and T-PFS
of first and second treatment (SU/SO vs. SO/SU). Laboratory tests
were performed at least every 4 weeks. Tumor assessments using
computed tomography was performed at baseline, week 8, and every
8 weeks thereafter until disease progression. AEs were graded using
the National Cancer Institute Common Terminology Criteria for
Adverse Events, version 3.0.10
Statistical Analysis
The present randomized trial tested the null hypothesis that the
mPFS with sunitinib was 11 months versus the alternative hy-
pothesis that mPFS with sorafenib was 5.5 months, with an mPFS
increase of 5.5 months or 100% improvement with sunitinib,
corresponding to a HR of 0.5 (overall 1-sided a of 0.01). To yield a
90% power for detecting a statistically significant difference
(P < .05) between the treatment arms, an estimated total of 116
patients were required for enrollment. Randomization and regis-
tration were performed by an independent organization, Universitynical Genitourinary Cancer Month 2020Hospital Medical Information Network Clinical Trial Registry
(Tokyo, Japan). The assignment was obtained at enrollment by the
investigator via the Internet, and the patients and investigator were
not blinded to the treatment.
Efficacies were analyzed in the intent-to-treat population (all
treatment-naive patients randomly assigned to 1 of the 2 groups).
Safety analyses were performed in the safety population, which
included all randomly assigned patients who had received  1 dose
of the drug. An interim futility analysis was planned for when 60
patients were evaluable (ie, w50% of those required for the final
analysis), and the data monitoring committee could consider early
trial discontinuation. The data in the present report were based on
the secondary interim analysis with a significance level set as
P ¼ .0151 using the O’Brien-Fleming method. The final analysis
was planned for August 2015, with P ¼ .0471.
The Kaplan-Meier method was used to estimate the mPFS, and
2-sided 95% CIs were calculated. The PFS rates between the 2
treatment arms were compared using the log-rank test. The Cox
proportional hazards model was used to estimate the HRs with
2-sided 95% CIs, with a significance level of P ¼ .05. The PFS rates
between the treatment arms were also compared on the basis of
baseline patient characteristics, including clinical T and M stage at
Yoshihiko Tomita et althe initial diagnosis; histologic grade of primary RCC; MSKCC risk
group; previous nephrectomy; cerebral, hepatic, pulmonary, or
osseous metastasis; leukocytopenia, neutropenia, lymphopenia, and
thrombocytopenia; serum C-reactive protein (CRP) level; number
of metastatic lesions; and overall diameter of the lesions using the
RECIST. The Kaplan-Meier method was used to estimate the
median duration of the response with a 2-sided 95% CI, and the
dose intensity was evaluated using the Mann-Whitney U test.
Results
Patients
From February 18, 2010 to July 15, 2012, 124 patients with
treatment-naive mCC-RCC were enrolled at 39 sites in Japan
(Supplemental Appendix in the online version). The demographic
and clinical characteristics of the enrolled patients at baseline were
balanced between the 2 treatment groups (Table 1), except for the
number of patients with stable BMs. More patients with BMs had
been included in the SU/SO arm than in the SO/SU arm (5 vs. 1),
which was not a statistically significant difference (P ¼ .071). Of the
124 patients, 60 and 64 were randomly assigned to the SU/SO and
SO/SU arms, respectively. Four patients withdrew their consent (3
and 1 in the SU/SO and SO/SU arms, respectively), and the
remaining 57 patients in the SU/SO arm and 63 patients in the SO/
SU arm received the assigned first-line treatment. At the data cutoff
date of June 30, 2015, 95% and 98% of the patients in the SU/SO
and the SO/SU arms, respectively, had discontinued the first-line
treatment, most frequently because of disease progression
(Figure 1). The median first-line treatment duration was relatively
longer (6.7 vs. 5.9 months; P ¼ .097) and the median relative dose
intensity (total dose administered/total dose assigned dose  100)
was greater (65.8% [range, 7.1%-100%] vs. 61.2% [range,
10.7%-100%]; P ¼ .333) with sunitinib than sorafenib. Subse-
quently, 30 of the 54 patients (56%) were administered sorafenib
after sunitinib, and 47 of the 62 patients (76%) were administered
sunitinib after sorafenib (P ¼ .030). At the data cutoff date, 1 of the
30 patients (3%) and 7 of the 47 patients (15%) had continued
treatment to receive sorafenib and sunitinib, respectively.
PFS and OS
The median first-PFS was longer with sunitinib than that with
sorafenib (8.7 months; 95% CI, 5.5-21.1 months; and 7.0 months;
95% CI, 6.1-12.2 months, respectively; Table 2 and Figure 2A).
The difference was not statistically significant (HR, 0.67; 95% CI,
0.42-1.08; 2-sided P ¼ .128). No statistically significant differences
were found between the sunitinib and sorafenib groups in T-PFS
(27.8 and 22.6 months, respectively; HR, 0.73; 95% CI,
0.428-1.246; P ¼ .247; Figure 2E) or OS (38.4 and 30.9 months,
respectively; HR, 0.934; 95% CI, 0.588-1.485; P ¼ .773;
Figure 2F).
The subgroup HR analyses for first-PFS of patients with serum
creatinine greater than the normal limit (n ¼ 61; HR, 0.525; 95%
CI, 0.277-0.995; P ¼ .04937); favorable MSKCC risk (n ¼ 26;
HR, 0.245; 95% CI, 0.082-0.734; P¼ .012); histopathologic grade
1 or 2 primary tumors (n ¼ 72; HR, 0.397; 95% CI, 0.213-0.742;
P ¼ .003); previous nephrectomy (n ¼ 106; HR, 0.602; 95% CI,
0.378-0.960; P ¼ .032); clinical stage T1 or T2 (n ¼ 58; HR,
0.283; 95% CI, 0.137-0.588; P < .001); stage M0 versus M1 at theinitial RCC diagnosis (n ¼ 56; HR, 0.411; 95% CI, 0.203-0.834;
P ¼ .012) and  4 metastatic lesions (n ¼ 63; HR, 0.406; 95% CI,
0.207-0.797; P ¼ .007) revealed that sunitinib was superior to
sorafenib. In contrast, sorafenib was superior to sunitinib for pa-
tients without previous nephrectomy (n ¼ 14; HR, 3.359; 95% CI,
1.016-11.100; P ¼ .046).
The T-PFS of the SU/SO arm was superior to that of the SO/SU
arm in the subgroup of patients with favorable MSKCC risk (HR,
0.164; 95% CI, 0.035-0.766; P ¼ .008) and those with < 5
metastatic sites (HR, 0.406; 95% CI, 0.207-0.797; P ¼ .009). In
contrast, the HR was lower in the SO/SU arm in the patients
without previous nephrectomy (HR, 11.816; 95% CI, 1.355-103;
P ¼ .007). No statistically significant differences were found in the
OS rates between the treatment groups in any of the subgroup
analyses (Figure 3).
Objective Response
The ORR was evaluated using RECIST, version 1.1. A complete
response (CR) determined by the assessment of the treating physi-
cian, was observed in 2 patients treated with sunitinib (4.3%) and 1
patient treated with sorafenib (2.1%) in first-line treatment
(Table 2). A partial response (PR) was observed in 12 patients
treated with sunitinib (25.5%) and 9 patients treated with sorafenib
(19.1%). The ORR (CR plus PR), although the difference was not
significant, was greater with sunitinib than with sorafenib (29.8%
vs. 21.2%; P ¼ .390). The median response duration was 32.0
months with sunitinib and 14.9 months with sorafenib. At the data
cutoff date, 3 of the 57 patients (5.0%) and 1 of the 63 patients
(1.6%) had continued to receive sunitinib and sorafenib, respec-
tively, as first-line treatment.
With second-line treatment, 3 patients (7.3%) had achieved a
CR with sunitinib; however, none of the patients had achieved CR
with sorafenib. A PR was observed in 6 patients with sunitinib
(14.6%) and 5 patients with sorafenib (21.7%). The ORR was not
significantly different between the 2 groups (21.9% and 21.7% with
sunitinib and sorafenib, respectively; P ¼ .984; Supplemental
Table 1 in the online version). The median response duration was
30.1 and 19.3 months with sunitinib and sorafenib, respectively. At
the data cutoff date, 1 of the 30 patients (3.3%) and 7 of the 47
patients (14.9%) had continued to receive sunitinib and sorafenib,
respectively, as second-line treatment.
Safety
The study patients had received sunitinib and sorafenib for a
median duration of 6.7 months (range, 0.1-45.3 months) and 6.1
months (range, 0.3-46.1 months), respectively, at the data cutoff
date (March 30, 2013; P ¼ .097). The most frequent all-grade, all-
causality AEs (ie, those detected in > 40% of patients) were hand-
foot syndrome (HFS), anorexia, fatigue, hypertension and stomatitis
with sunitinib and HFS, rash, hypertension, fatigue, and diarrhea
with sorafenib. The laboratory abnormalities included thrombocy-
topenia, neutropenia, proteinuria, hypothyroidism, increased lipase,
and decreased serum albumin with sunitinib and increased lipase,
proteinuria, increased aspartate transaminase, increased alanine
transaminase, and thrombocytopenia with sorafenib (Table 3).
The AEs that occurred more frequently ( 15% difference) with
sunitinib than with sorafenib were anorexia, nausea, vomiting,Clinical Genitourinary Cancer Month 2020 - 5
Figure 1 Consolidated Standards of Reporting Trials Diagram
Patients randomly assigned
(n = 124)
assigned to Arm A 
(sunitinib)
(n = 60)











Continued sunitinib (n = 3)
Discontinued sunitinib (n = 54)
Continued sorafenib (n = 1)
Discontinued sorafenib (n = 62)
Continued sorafenib (n = 1)









Continued sunitinib (n = 7)
Discontinued sunitinib (n = 40)
Table 2 Best Tumor Responsea and Progression-free Survival





(n [ 63) P Valueb
Objective
response
14 (29.8) 10 (21.3) .390
Complete
response
2 (4.3) 1 (2.1)
Partial response 12 (25.5) 9 (19.1)
Stable disease 14 (30.0) 22 (46.8)
Progressive
disease











Median, mo 8.7 7.0
95% CI, mo 5.5-21.1 6.1-12.2
Abbreviation: CI ¼ confidence interval.
aTumor response was assessed using the Response Evaluation Criteria in Solid Tumors, version
1.1.
bCalculated using the c2 test for the objective response and log-rank test for progression-free
survival.
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6 - Clistomatitis, fatigue, fever, neutropenia, thrombocytopenia, hypo-
thyroidism, low hemoglobin, increased creatinine, and decreased
serum albumin. In contrast, those that occurred more frequently
with sorafenib than with sunitinib were rash, diarrhea, and HFS
(Table 3).
Grade  3 AEs were reported in 98 patients (81.7%) in the
entire study, including 50 (79.4%) and 48 (84.2%) patients treated
with sunitinib and sorafenib, respectively. The grade  3 AEs that
occurred more frequently ( 5% difference) in patients treated with
sunitinib were anorexia, nausea, fatigue, low hemoglobin, neu-
tropenia, thrombocytopenia, and hyponatremia. In contrast,
increased aspartate transaminase, increased alanine transaminase,
diarrhea, rash, and HFS occurred more frequently in those treated
with sorafenib. A total of 13 (22.8%) and 12 (19.0%) patients in
the sunitinib and sorafenib groups, respectively, discontinued
therapy because of treatment-related AEs. One grade 5 AE,
gastrointestinal perforation, was reported during sorafenib
treatment.
For second-line treatment, the patients had received sunitinib
and sorafenib for a median duration of 4.1 months (range, 0.6-46.4
months) and 3.3 months (range, 0.2-35.6 months), respectively
(P ¼ .361). The most frequent all-grade, all-causality AEs (AEs
detected in > 40% of patients) were HFS, anorexia, hypothyroid-
ism, and fatigue with sunitinib and HFS, hypothyroidism, and rash
with sorafenib. Although the rate of patients with fatigue was almost
identical between the first-line and second-line sunitinib groups
(58% and 51%, respectively), the rate of patients with fatigue was
lower among those with second-line sorafenib (23%) compared
with those with first-line sorafenib (44%). The incidence of HFS
was lower in both second-line sunitinib and sorafenib groups. The
changes in the rates of other AEs and laboratory abnormalities were
comparable, albeit occurring at lower frequencies (Supplemental
Table 2 in the online version).nical Genitourinary Cancer Month 2020Grade  3 AEs were reported in 30 patients (39.0%) during
second-line treatment, including 15 (51.7%) and 15 (31.3%) pa-
tients treated with sunitinib and sorafenib, respectively. The
grade  3 AEs that occurred more frequently ( 5%) in patients
treated with sunitinib were anorexia and fatigue. A total of 5 pa-
tients (10.6%) treated with sunitinib and 8 (26.7%) treated with
sorafenib discontinued therapy because of treatment-related AEs.
One grade 5 AE, pneumonitis, was reported during sorafenib
treatment (Supplemental Table 2 in the online version).
Discussion
The present randomized trial was designed to elucidate the pre-
viously unreported comparison of 2 active compounds, sunitinib
and sorafenib, as first-line treatment of mRCC. Because temsir-
olimus was demonstrated to prolong OS for patients with poor
MSKCC risk,6 the present trial was prespecified to patients with
favorable and intermediate MSKCC risk. Thus, all patients with a
diagnosis of CC-RCC were enrolled, and no patient with non-CC
histologic features was enrolled. The trial was determined on the
hypothesis of a 5.5-month improvement in mPFS with sunitinib
compared with sorafenib.4,11 In the present study, no significant
difference in mPFS was found between the patients treated with
sunitinib and sorafenib, although the survival duration was
numerically longer with sunitinib. Sorafenib, chosen as the active
comparator, was originally reported to prolong PFS as second-line
treatment in patients pretreated with cytokines. The mPFS of sor-
afenib, 5.5 months, was used to design the present study. In the
present study, the mPFS of sorafenib was 7.0 months, which was
longer than expected. A randomized trial of tivozanib versus sor-
afenib as first-line therapy (TIVO-1) also reported a longer mPFS
Figure 2 Kaplan-Meier Curve Estimated (A) Progression-free Survival (PFS) in First Assigned Treatment (Sunitinib or Sorafenib), (B)
Time to Treatment Failure in First Assigned Treatment, (C) PFS in Sequential Treatment (Sorafenib After Sunitinib Treatment
or Sunitinib After Sorafenib Treatment), (D) Time to Treatment Failure in Sequential Treatment, (E) Total PFS (Sunitinib to
Sorafenib or Sorafenib to Sunitinib), and (F) Overall Survival
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Yoshihiko Tomita et al(9.1 months; 95% CI, 7.3-9.5 months) in the sorafenib arm.12 In
another randomized trial comparing axitinib with sorafenib in
treatment-naive patients, sorafenib was also associated with a longer
mPFS of 6.5 months (95% CI, 4.7-8.3 months).13 Another single-
arm trial assessing sorafenib as first-line treatment also found mPFS
longer than 5.5 months with the treatment.14,15 In the present
study, the mPFS with first-line sorafenib was 7.0 months (95% CI,
6.3-7.7 months), comparable with previously reported results.
Whether 1 of the clones in primary RCC develops into metastatic
lesions has been a focus of intense debate, and the characteristics of
primary RCC cells are not identical to those of the metastatic le-
sions. Systematic comprehensive investigation of primary and
metastatic lesions revealed several common genetic alterations, at
least partially,16 and key genetic and molecular alterations might be
retained throughout the targeted therapy.17,18 In the present study,
of the factors predicting for longer PFS with first-line sunitinib
treatment, clinical stage T1 or T2 and/or lower primary tumor
grade reflected the less aggressive features of the tumor cells. An
elevated CRP, which corresponds to aggressiveness in RCC, is
associated with a predisposition to a worse prognosis.19 Corre-
spondingly, the patients with lower CRP levels achieved longer PFS
with sunitinib in the present study.
As a more direct clinical implication, significantly longer PFS was
observed with sunitinib among patients with favorable risk than
those with intermediate risk. In previous studies comparing PFS of
more specific tyrosine kinase inhibitors (TKIs) targeted against
VEGFR, tivozanib and axitinib, with sorafenib as first-line ther-
apy,12,15 the selective TKIs led to longer PFS for patients with
favorable risk than that for those with intermediate risk. In the firstclinical trial of sorafenib,11 the HR for PFS for patients with in-
termediate risk was lower than that for those with favorable risk.
Thus, selective TKIs with more specificity for VEGFR are expected
to provide more benefit for patients with less aggressive mRCC.12,20
The patients with intermediate risk comprise a heterogeneous
population, with associated differences in clinical outcomes21; thus,
a detailed examination of patients with intermediate risk is necessary
to determine the susceptibility toward specific drugs. In the context
of risk factors, the efficacy of the combination of the immune
checkpoint inhibitors ipilimumab and nivolumab as first-line ther-
apy was associated with a longer median OS compared with that
with sunitinib for patients with intermediate and poor prognoses
using the IMDC criteria.22 A randomized controlled trial that
compared cabozantinib, a broad TKI against c-Met and VEGFR2,
which also inhibits AXL and RET, and sunitinib in 167 patients
with treatment-naive mRCC with intermediate or poor IMDC risk
revealed that the mPFS duration was 8.6 months (95% CI, 6.8-14.0
months) with cabozantinib and 5.3 months (95% CI, 3.0-8.2
months) with sunitinib (HR, 0.48; 95% CI, 0.31-0.74; P ¼
.0008).23 The results of these 2 clinical trials, albeit evaluating
different drugs, suggest that the benefit of sunitinib treatment can
be expected in patients with mRCC and relatively fewer poor
prognostic factors. In addition to the data regarding sorafenib as
first-line treatment in the present study, it might be worthwhile to
compare sorafenib with the new TKIs, such as cabozantinib, or a
combination of nivolumab and ipilimumab, as first-line therapy
specifically for patients with intermediate or poor MSKCC risk.
No statistically significant differences were found in the
secondary outcome measures of the present study, includingClinical Genitourinary Cancer Month 2020 - 7
Figure 3 Cox Progression Hazards Analysis of Progression-free Survival (PFS) With First-Line Therapy and Total Protocol Treatment
and Overall Survival (OS) Stratified by Various Patient Baseline Factors (Extracts)
Abbreviations: Cre ¼ creatinine; CRP ¼ C-reactive protein; fav ¼ favorable (risk); G ¼ grade; int ¼ intermediate (risk); mets ¼ metastasis; Nx ¼ any node stage; UNL ¼ upper normal limit.
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8 - CliT-PFS and OS. Targeted drugs for mRCC have been approved
by the positive (ie, statistically significant) results of, not OS,
but PFS, in randomized trials, except for a trial comparing
temsirolimus with IFN-a6 and a phase II trial comparing len-
vatinib plus everolimus with everolimus alone in a second-line
treatment setting.24 In contrast, recent studies evaluating the
immune checkpoint inhibitor nivolumab alone in a sequential
treatment setting25 and nivolumab and ipilimumab in a first-
line setting22 demonstrated significant differences, not in PFS,
but in OS rates. At the cutoff date for the present study, no
patients had received treatment with an immune checkpoint
inhibitor; therefore, the data in the present study should be
assessed with other studies conducted in the pre-immune
checkpoint inhibitor era.
Conclusions
The primary endpoint of first-PFS for sunitinib compared with
sorafenib was not met. Sunitinib appeared to be more active than
sorafenib for patients with mCC-RCC and the following clinicopath-
ologic characteristics: favorableMSKCC risk, no BMs, primary cT1 or
T2 but not  T3, lower histologic grade, and CRP  1 mg/mL.nical Genitourinary Cancer Month 2020Clinical Practice Points
 The median first-PFS was 8.7 and 7.0 months in the SU/SO and
SO/SU groups, respectively; however, the primary endpoint of
first-PFS was not met.
 The T-PFS and OS were similar between the SU/SO and SO/SU
groups (27.8 and 22.6 months; HR, 0.73; 95% CI, 0.428-
1.246; and 38.4 and 30.9 months; HR, 0.934; 95% CI, 0.588-
1.485, respectively).
 Sunitinib appeared to be more active than sorafenib in pa-
tients with mCC-RCC and the following clinicopathologic
characteristics: favorable MSKCC risk, no BMs, primary cT1
or cT2 but not cT3, lower histologic grade, and CRP  1
mg/mL.Acknowledgments
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Table 3 Adverse Events and Laboratory Abnormalities With First Assigned Treatment
Variable
Sunitinib Sorafenib
P ValueAll Grades Grade 3-4 Grade 5 All Grades Grade 3-4 Grade 5
AEs
Hand-foot syndrome 40 (70) 7 (12) 0 (0) 54 (86) 16 (25) 0 (0) .077
Anorexia 37 (65) 6 (11) 0 (0) 26 (41) 0 (0) 0 (0) .001
Hypothyroidism 37 (65) 0 (0) 0 (0) 19 (30) 2 (3) 0 (0) <.001
Fatigue 33 (58) 9 (16) 0 (0) 28 (44) 1 (2) 0 (0) .026
Hypertension 32 (56) 10 (18) 0 (0) 28 (44) 12 (19) 0 (0) .474
Stomatitis 26 (46) 2 (4) 0 (0) 14 (22) 0 (0) 0 (0) .022
Nausea 19 (33) 3 (5) 0 (0) 7 (11) 0 (0) 0 (0) .011
Rash 14 (25) 1 (2) 0 (0) 31 (49) 9 (14) 0 (0) .022
Diarrhea 14 (25) 0 (0) 0 (0) 28 (44) 4 (6) 0 (0) .084
Vomiting 13 (23) 1 (2) 0 (0) 2 (3) 0 (0) 0 (0) .012
Fever 9 (16) 0 (0) 0 (0) 3 (5) 0 (0) 0 (0) .045
Hemorrhage, GI 2 (4) 2 (4) 0 (0) 1 (2) 0 (0) 0 (0) .709
LV systolic dysfunction 1 (2) 0 (0) 0 (0) 1 (2) 1 (2) 0 (0) .157
Cardiac ischemia 1 (2) 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) NA
Perforation, GI 0 (0) 0 (0) 0 (0) 1 (0) 1 (2) 1 (2) NA
Edema, limb 0 (0) 0 (0) 0 (0) 1 (2) 1 (2) 0 (0) NA
Infection (lung) 0 (0) 0 (0) 0 (0) 1 (2) 1 (2) 0 (0) NA
Joint function 0 (0) 0 (0) 0 (0) 1 (2) 1 (2) 0 (0) NA
Urinary retention 0 (0) 0 (0) 0 (0) 1 (2) 1 (2) 0 (0) NA
Laboratory abnormalities
Thrombocytopenia 51/57 (89) 19/57 (33) 0 (0) 27/62 (44) 1/62 (2) 0 (0) <.001
Leukopenia 48/57 (84) 5/57 (9) 0 (0) 11/62 (18) 0/62 (0) 0 (0) <.001
Neutropenia 42/53 (79) 15/53 (28) 0 (0) 10/56 (18) 0/62 (0) 0 (0) <.001
Lymphopenia 41/53 (77) 10/53 (19) 0 (0) 32/55 (58) 5/55 (9) 0 (0) .123
Proteinuria 34/47 (72) 2/47 (4) 0 (0) 31/54 (57) 4/54 (7) 0 (0) .074
Lipase 23/35 (66) 4/35 (11) 0 (0) 24/39 (62) 8/39 (21) 0 (0) .475
Albumin serum, low 37/56 (66) 4/56 (7) 0 (0) 24/61 (39) 2/61 (3) 0 (0) .021
Anemia 35/57 (61) 7/57 (12) 0 (0) 15/62 (24) 3/62 (5) 0 (0) .001
AST elevation 35/57 (61) 4/57 (7) 0 (0) 32/62 (52) 8/62 (13) 0 (0) .244
Creatinine 30/57 (53) 0/57 (0) 0 (0) 13/63 (21) 1/63 (2) 0 (0) .001
ALT elevation 29/57 (51) 6/57 (11) 0 (0) 30/62 (48) 10/62 (16) 0 (0) .030
Amylase 21/48 (44) 3/48 (6) 0 (0) 23/55 (42) 3/55 (5) 0 (0) .867
Hyponatremia 24/56 (43) 8/56 (14) 0 (0) 20/62 (32) 3/62 (5) 0 (0) .187
ALP elevation 23/55 (42) 1/55 (2) 0 (0) 24/62 (39) 0/62 (0) 0 (0) .753
Hyperkalemia 19/56 (34) 2/56 (4) 0 (0) 21/62 (34) 0/62 (0) 0 (0) .413
Hyperuricemia 18/56 (32) 2/56 (4) 0 (0) 13/59 (22) 0/50 (0) 0 (0) .224
Bilirubin 10/56 (18) 1/56 (2) 0 (0) 8/62 (13) 1/62 (2) 0 (0) .153
Data presented as n (%) or n/N (%).
Abbreviations: AEs ¼ adverse events; ALP ¼ alkaline phosphatase; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; GI ¼ gastrointestinal; LV ¼ left ventricular; NA ¼ not
applicable.
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(n [ 47) P Valueb
Objective
response
5 (21.7) 9 (21.9 .984
Complete
response
0 (0.0) 3 (7.3)
Partial response 5 (21.7) 6 (14.6)
Stable disease 6 (26.1) 9 (22.0)
Progressive
disease











Median, mo 4.7 4.7
95% CI, mo 2.3-15.4 3.8-13.4
Abbreviation: CI ¼ confidence interval.
aTumor response was assessed using the Response Evaluation Criteria in Solid Tumors, version
1.1.
bCalculated using the c2 test for the objective response and log-rank test for progression-free
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Supplemental Table 2 Adverse Eventsa and Laboratory Abnormalities With Sequential Treatment
Variable
Sorafenib (n [ 30) Sunitinib (n [ 47)
P ValueAll Grades Grade 3-4 Grade 5 All Grades Grade 3-4 Grade 5
AEs
Hand-foot syndrome 14 (47) 1 (3) 0 (0) 21 (45) 2 (4) 0 (0) .954
Anorexia 6 (20) 0 (0) 0 (0) 19 (40) 3 (6) 0 (0) .215
Hypothyroidism 9 (65) 0 (0) 0 (0) 22 (47) 1 (2) 0 (0) .246
Fatigue 7 (23) 1 (3) 0 (0) 24 (51) 6 (13) 0 (0) .033
Hypertension 7 (23) 3 (10) 0 (0) 16 (34) 3 (6) 0 (0) .380
Stomatitis 3 (10) 1 (3) 0 (0) 12 (26) 0 (0) 0 (0) .009
Nausea 4 (13) 0 (0) 0 (0) 12 (26) 0 (0) 0 (0) .324
Rash 9 (65) 2 (7) 0 (0) 5 (11) 1 (2) 0 (0) .028
Diarrhea 6 (20) 1 (3) 0 (0) 9 (19) 1 (2) 0 (0) 1.000
Vomiting 3 (30) 0 (0) 0 (0) 7 (15) 0 (0) 0 (0) .732
Fever 2 (7) 1 (3) 0 (0) 8 (17) 0 (0) 0 (0) .039
Hemorrhage, GI 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) NA
Cardiac ischemia 1 (3) 1 (3) 0 (0) 0 (0) 0 (0) 0 (0) NA
Edema, limb 2 (7) 2 (7) 0 (0) 3 (6) 0 (0) 0 (0) .200
Infection (lung) 0 (0) 0 (0) 1 (3) 1 (2) 0 (0) 0 (0) .026
Joint function 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) NA
Urinary retention 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) NA
LV systolic dysfunction 1 (3) 1 (3) 0 (0) 1 (2) 0 (0) 0 (0) 1.000
Perforation, GI 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) NA
Hiccoughs 0 (0) 0 (0) 0 (0) 1 (2) 1 (2) 0 (0) NA
Laboratory abnormalities
Thrombocytopenia 6/26 (23) 0/26 (0) 0 (0) 38/44 (86) 14/44 (32) 0 (0) <.001
Leukopenia 4/23 (17) 0/23 (0) 0 (0) 37/44 (84) 4/44 (9) 0 (0) <.001
Lymphopenia 13/25 (52) 4/25 (16) 0 (0) 31/42 (74) 7/42 (17) 0 (0) .374
Neutropenia 1/25 (4) 0/25 (0) 0 (0) 33/42 (79) 15/42 (36) 0 (0) <.001
Proteinuria 13/22 (59) 2/22 (9) 0 (0) 17/36 (47) 2/36 (6) 0 (0) .231
Albumin serum, low 8/26 (31) 0/26 (0) 0 (0) 18/41 (44) 3/41 (7) 0 (0) .470
Lipase 7/16 (44) 2/16 (13) 0 (0) 14/32 (44) 3/32 (9) 0 (0) .770
AST elevation 6/26 (23) 0/26 (0) 0 (0) 23/44 (52) 2/44 (5) 0 (0) .088
Anemia 7/24 (29) 3/24 (13) 0 (0) 20/44 (45) 3/44 (7) 0 (0) .256
Creatinine 7/26 (27) 3/26 (12) 0 (0) 19/44 (43) 2/44 (5) 0 (0) .160
ALT elevation 6/26 (23) 0/26 (0) 0 (0) 16/44 (36) 2/44 (5) 0 (0) .667
Amylase 5/24 (21) 1/24 (4) 0 (0) 15/39 (38) 3/39 (8) 0 (0) .156
Hyponatremia 16/44 (36) 3/44 (7) 0 (0) 9/25 (36) 3/25 (12) 0 (0) .738
ALP elevation 7/24 (29) 0/24 (0) 0 (0) 12/42 (28) 1/42 (2) 0 (0) 1.000
Hyperkalemia 10/26 (38) 0/26 (0) 0 (0) 15/43 (15) 1/43 (2) 0 (0) .762
Hyperuricemia 7/24 (29) 2/24 (8) 0 (0) 6/39 (15) 1/39 (3) 0 (0) .183
Bilirubin 1/25 (4) 0/25 (0) 0 (0) 12/40 (30) 2/40 (5) 0 (0) .054
Data presented as n (%) or n/N (%).
Abbreviations: AEs ¼ adverse events; ALP ¼ alkaline phosphatase; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; GI ¼ gastrointestinal; LV ¼ left ventricular; NA ¼ not
applicable.
aAll AEs occurring in > 10% of sunitinib or sorafenib groups and those with grade 3, 4, or 5; AEs and laboratory abnormalities were determined using the National Cancer Institute Common
Terminology Criteria for Adverse Events.
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